Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$34.64 USD
-0.64 (-1.81%)
Updated Jun 10, 2024 04:00 PM ET
After-Market: $35.31 +0.67 (1.93%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Celldex Therapeutics, Inc. [CLDX]
Reports for Purchase
Showing records 361 - 380 ( 412 total )
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CDX-011 Update; More Positive Trends EMERGE-ing; Target Upped to $11
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare -ASH 2012 Preview: Expecting Exciting Data in Atlanta
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of November 18
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive and Consistent Rindo 3-Year Survival Data Bode Well for ACT IV
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3:12 Update - Data Filled Q4 with Broader Commercial Strategy Emerging in 2013
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PTI Platform Continues to Shine; Key ''011 Update Soon: Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of October 14
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
September 2012 Potential Catalysts & Milestones - Monthly Update
Provider: WEDBUSH SECURITIES INC.
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Life Sciences MAC Best Ideas Conference - New York City
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
June 2012 Potential Catalysts & Milestones - Monthly Update
Provider: WEDBUSH SECURITIES INC.
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CDX-011 EMERGEs Victorious from Randomized Phase IIb Study
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J